The ACVR1 Knouckout HCT 116 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal population derived from the HCT 116 human colorectal carcinoma cell line, engineered for disruption of the ACVR1 gene. This knockout model provides a loss-of-function system to investigate ACVR1-dependent signaling in a malignant colonic epithelial context. The polyclonal nature ensures a heterogeneous gene-edited pool, avoiding clonal selection biases, and is suitable for population-level studies of BMP receptor biology.
HCT 116 is a well-characterized human colorectal carcinoma cell line exhibiting microsatellite instability and an oncogenic KRAS mutation (G13D), reflecting key genetic features of sporadic CRCs. These cells display malignant properties including rapid proliferation, anchorage-independent growth, and invasive capacity, making them a valuable platform for examining tumor suppressor or oncogenic functions of BMP signaling.
ACVR1 functions as a type I serine/threonine kinase receptor that initiates BMP signal transduction upon ligand engagement. BMP ligands such as BMP2, BMP4, BMP6, and BMP7 bind to preformed heteromeric complexes of ACVR1 with type II receptors (BMPR2, ACVR2A), triggering phosphorylation of regulatory SMADs (SMAD1/5/8). Phosphorylated SMAD1/5/8 form heterocomplexes with SMAD4, which translocate to the nucleus to regulate transcription of target genes including ID1, ID2, RUNX2, and SPP1. The pathway is modulated by extracellular antagonists like Noggin and Follistatin, as well as intracellular regulators such as FKBP12 and SARA. This signaling network governs diverse cellular outcomes including proliferation, differentiation, and apoptosis.
In the HCT 116 colorectal carcinoma context, where basal BMP signaling may exert tumor-suppressive effects, ACVR1 disruption allows dissection of receptor-dependent versus independent functions. This model facilitates investigation of how ACVR1-mediated SMAD1/5/8 phosphorylation influences malignant phenotypes such as proliferation, migration, and invasion, which are commonly dysregulated in microsatellite-unstable CRCs. Moreover, while gain-of-function ACVR1 variants drive Fibrodysplasia Ossificans Progressiva and are implicated in Diffuse Intrinsic Pontine Glioma, this knockout system provides a contrasting loss-of-function tool to evaluate ACVR1 dependency in heterotopic ossification research and to screen for inhibitors that may paradoxically activate or rescue pathway activity.
Researchers can utilize these ACVR1 knockout cells to interrogate BMP pathway contributions to colorectal tumorigenesis through Western blot analysis of phospho-SMAD1/5/8 levels, RT-qPCR profiling of ID1 and ID2 expression, and BMP-responsive luciferase reporter assays. Functional studies measuring cell proliferation, migration, invasion, and apoptosis under basal and BMP-stimulated conditions enable assessment of ACVR1??s role in cancer progression or suppression. Moreover, this polyclonal knockout pool is well-suited for high-throughput drug screening campaigns aimed at identifying ACVR1 modulators or downstream pathway inhibitors. For further information or to discuss custom applications, please contact Ascent Research.
